The DOI matches its Crossref record; 107 of the 107 references it cites were found in a registry or an index.
Cardiovascular Risk of Nonsteroidal Anti‐inflammatory Drugs and Classical and Selective Cyclooxygenase‐2 Inhibitors: A Meta‐analysis of Observational Studies
Open accessAbstract
The purpose of this study was to review the published evidence on the clinical use of nonsteroidal anti‐inflammatory drugs (NSAIDs) and to assess the cardiovascular risk (CVR) of cyclooxygenase‐2 inhibitors (coxibs), excluding aspirin, by means of a meta‐analytic procedure. A search was conducted on MEDLINE and EMBASE databases between October 1999 and June 2018. Cohort and case‐control studies showing CVR as relative risk (RR), odds ratio, hazard ratio, or incidence rate ratio associated with NSAIDs versus no treatment were selected. We estimated the pooled RR and the 95% confidence interval (CI) for all NSAIDs as a whole and individually. Eighty‐seven studies met the inclusion criteria. Overall, NSAIDs were found to be associated with a statistically significantly increased CVR (RR, 1.24 [95%CI, 1.19‐1.28]). The risk was slightly higher for coxibs (RR, 1.22 [95%CI, 1.17‐1.28]) as compared with nonselective NSAIDs (RR, 1.18 [95%CI, 1.12‐1.24]). Data analysis by drug disclosed that rofecoxib (RR, 1.39 [95%CI, 1.31‐1.47]), followed by diclofenac (RR, 1.34 [95%CI, 1.26‐1.42]) and etoricoxib (RR, 1.27 [95%CI, 1.12‐1.43]) were the NSAIDs associated with the highest CVR. Analysis by type of event showed that the highest risk corresponded to vascular events for both coxibs (RR, 2.18 [95%CI, 1.72‐2.78]) and nonselective NSAIDs (RR, 2.46 [95%CI, 2.00‐3.02]). The meta‐analysis results suggest that the use of the marketed coxibs celecoxib and etoricoxib would be related to a statistically significant CVR increase. Etoricoxib CVR could be higher than that for celecoxib. This increment would be similar to classical NSAID CVR.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“NSAIDs significantly increase the risk of cardiovascular adverse outcomes.93”
Citations
Cites
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011233432103 · Cited by 4,027
Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050493 · Cited by 2,519
Kearney, P. M., Baigent, C., Godwin, J., Halls, H., Emberson, J. R., & Patrono, C. (2006) · BMJ · doi:10.1136/bmj.332.7553.1302 · Cited by 1,445
Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis
Trelle, S., Reichenbach, S., Wandel, S., Hildebrand, P., Tschannen, B., Villiger, P. M., Egger, M., & Juni, P. (2011) · BMJ · doi:10.1136/bmj.c7086 · Cited by 1,166
McGettigan, P., & Henry, D. (2006) · JAMA · doi:10.1001/jama.296.13.jrv60011 · Cited by 1,096
Graham, D. J., Campen, D., Hui, R., Spence, M., Cheetham, C., Levy, G., Shoor, S., & Ray, W. A. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17864-7 · Cited by 913
Research works printed but not linked: 3
- Higgins JPT, 2011, Manual Cochrane de revisionessistemáticas de intervenciones, Cochrane, 1
- Sanchez Serrano JL, 2015, Cardiovascular risk associated with the use of nonsteroidal anti‐inflammatory drugs, Rev Esp Salud Publica, 89, 607
- Gutiérrez Dávila JM, 2007, Texto de Cardiología [Cardiology Text], 1145
Cited by
Management of Osteoarthritis: Expert Opinion on NSAIDs
Magni, A., Agostoni, P., Bonezzi, C., Massazza, G., Menè, P., Savarino, V., & Fornasari, D. (2021) · Pain and Therapy · doi:10.1007/s40122-021-00260-1 · Cited by 201
Mallet, C., Desmeules, J., Pegahi, R., & Eschalier, A. (2023) · Journal of Pain Research · doi:10.2147/jpr.s393809 · Cited by 83
“NSAIDs significantly increase the risk of cardiovascular adverse outcomes.(93) No robust evidence supports an association between paracetamol and adverse cardiovascular outcomes (stroke or myocardial infarction) in patients with atherosclerotic heart diseases.”
BackgroundCurrent Nanoparticle-Based Technologies for Osteoarthritis Therapy
Jin, G. (2020) · Nanomaterials · doi:10.3390/nano10122368 · Cited by 75
Inclusion Complexes of Non-Steroidal Anti-Inflammatory Drugs with Cyclodextrins: A Systematic Review
Miranda, G. M., Santos, V. O. R. E., Bessa, J. R., Teles, Y. C. F., Yahouédéhou, S. C. M. A., Gonçalves, M. D. S., & Ribeiro‐Filho, J. (2021) · Biomolecules · doi:10.3390/biom11030361 · Cited by 63
Therapeutic implications of cyclooxygenase (COX) inhibitors in ischemic injury
Khan, H., Sharma, K., Kumar, A., Kaur, A., & Singh, T. G. (2022) · Inflammation Research · doi:10.1007/s00011-022-01546-6 · Cited by 62
Salis, Z., & Sainsbury, A. (2024) · Scientific Reports · doi:10.1038/s41598-024-56665-3 · Cited by 68
Walker, C. (2018) · International Journal of Rheumatology · doi:10.1155/2018/1302835 · Cited by 54
Alrouji, M., Al-Kuraishy, H. M., Al-Gareeb, A. I., Saad, H. M., & Batiha, G. E.-S. (2023) · Inflammopharmacology · doi:10.1007/s10787-023-01192-2 · Cited by 47
The Risks or Lack Thereof of Migraine Treatments in Vascular Disease
Diener, H. (2020) · Headache The Journal of Head and Face Pain · doi:10.1111/head.13749 · Cited by 45
Liu, P., Gu, L., Ren, L., Chen, J., Li, T., Wang, X., Yang, J., Chen, C., & Sun, L. J. (2019) · PubMed Central · Cited by 38
Schmidt, M., Sørensen, H. T., & Pedersen, L. H. (2022) · Drug Safety · doi:10.1007/s40264-022-01211-1 · Cited by 34
Unraveling the Role of Drug-Lipid Interactions in NSAIDs-Induced Cardiotoxicity
Pereira‐Leite, C., Figueiredo, M., Burdach, K., Nunes, C., & Reis, S. (2020) · Membranes · doi:10.3390/membranes11010024 · Cited by 30
Gleich, J., Pfeufer, D., Zeckey, C., Böcker, W., Gosch, M., Kammerlander, C., & Neuerburg, C. (2019) · European journal of medical research · doi:10.1186/s40001-019-0362-0 · Cited by 26
Tawfik, A. G., Gómez-Lumbreras, A., Fiol, G. D., Kawamoto, K., Trinkley, K. E., Reese, T., Jones, A. E., & Malone, D. C. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70054 · Cited by 40
Bonnesen, K., & Schmidt, M. (2021) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2021.06.014 · Cited by 28
Watanabe, Y., Imanishi, Y., Ozawa, H., Sakamoto, K., Fujii, R., Shigetomi, S., Habu, N., Otsuka, K., Sato, Y., Sekimizu, M., et al. (2020) · PubMed · Cited by 23
Metabolite G-Protein Coupled Receptors in Cardio-Metabolic Diseases
Strassheim, D., Sullivan, T., Irwin, D. C., Gerasimovskaya, E. V., Lahm, T., Klemm, D. J., Dempsey, E. C., Stenmark, K. R., & Karoor, V. (2021) · Cells · doi:10.3390/cells10123347 · Cited by 23
Xie, F., Xu, L., Zhu, H., Chen, Y., Li, Y., Nong, L., Zeng, Y., & Cen, S. (2022) · Molecules · doi:10.3390/molecules27082465 · Cited by 19
Zebenholzer, K., Gall, W., Gleiß, A., Pavelić, A. R., & Wöber, C. (2022) · Headache The Journal of Head and Face Pain · doi:10.1111/head.14304 · Cited by 14
Forbes, W., Petway, J., Gressler, L. E., Thorfinnson, H., Costantino, R. C., & Atkinson, T. J. (2024) · Journal of Pain Research · doi:10.2147/jpr.s440802 · Cited by 15
Insights from pharmacovigilance and pharmacodynamics on cardiovascular safety signals of NSAIDs
Liang, S., Wang, X., & Zhu, X. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1455212 · Cited by 17
Rayan, S. A., George, R. F., & Said, M. F. (2024) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2024.140148 · Cited by 13
Waswa, E. N., Muema, F. W., Odago, W. O., Mutinda, E. S., Nanjala, C., Mkala, E. M., Amenu, S. G., Ding, S.-X., Li, J., & Hu, G. (2022) · Pharmaceuticals · doi:10.3390/ph15070905 · Cited by 19
Wan, E. Y. F., Yu, E. Y. T., Chan, L. S., Mok, A. H. Y., Wang, Y., Chan, E. W., Wong, I. C. K., & Lam, C. L. K. (2022) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2142 · Cited by 12
Han, H., Ro, D., Han, H.-S., & Won, S.-A. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1539328 · Cited by 12
Triptans for Migraine Patients With Vascular Risks: New Insights, New Options
Leroux, É., & Rothrock, J. F. (2019) · Headache The Journal of Head and Face Pain · doi:10.1111/head.13656 · Cited by 10
Громова, О. А., Torshin, I. Y., Lila, A. M., Наумов, А. В., & Владимирович, Р. К. (2019) · Modern Rheumatology Journal · doi:10.14412/1996-7012-2019-1-129-134 · Cited by 10
Dogra, A., Kour, D., Gour, A., Bhardwaj, M., Bag, S., Dhiman, S. K., Kumar, A., Singh, G., & Nandi, U. (2022) · Drug and Chemical Toxicology · doi:10.1080/01480545.2022.2069804 · Cited by 10
Rajamohan, R., Muthuraja, P., Murugavel, K., Mani, M. K., Prabakaran, D. S., Seo, J. H., Malik, T., & Lee, Y. R. (2025) · Scientific Reports · doi:10.1038/s41598-024-84745-x · Cited by 12
Bonnesen, K., Ehrenstein, V., Grønkjær, M. S., Pedersen, L. H., Lash, T. L., & Schmidt, M. (2022) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5571 · Cited by 9
Marcianò, G., Muraca, L., Rania, V., & Gallelli, L. (2023) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2258 · Cited by 8
Kuźbicki, Ł., & Brożyna, A. A. (2020) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000871 · Cited by 8
Hypersensitivity reactions to non‐steroidal anti‐inflammatory drugs (NSAIDs) – a retrospective study
Angeletti, F., Meier, F., Zöller, N. N., Meißner, M., Kaufmann, R., & Valesky, E. M. (2020) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.14292 · Cited by 8
Torshin, I. Y., Lila, A. M., Naumov, A. V., Sardaryan, I. S., Bogacheva, T. E., Гришина, Т. Р., Викторовна, Г. И., Лиманова, О. А., & Громова, О. А. (2021) · FARMAKOEKONOMIKA Modern Pharmacoeconomics and Pharmacoepidemiology · doi:10.17749/2070-4909/farmakoekonomika.2021.077 · Cited by 8
Bonnesen, K., Pedersen, L. H., Ehrenstein, V., Grønkjær, M. S., Sørensen, H. T., Hallas, J., Lash, T. L., & Schmidt, M. (2023) · Drug Safety · doi:10.1007/s40264-023-01298-0 · Cited by 7
Komatsu, R., Singleton, M. D., Dinges, E. M., Wu, J., & Bollag, L. A. (2024) · JA Clinical Reports · doi:10.1186/s40981-024-00712-5 · Cited by 7
The Additive Antinociceptive Effect of Resveratrol and Ketorolac in the Formalin Test in Mice
Rojas-Aguilar, F. A., Briones-Aranda, A., Jaramillo‐Morales, O. A., Romero‐Nava, R., Esquinca-Avilés, H. A., & Espinosa‐Juárez, J. V. (2023) · Pharmaceuticals · doi:10.3390/ph16081078 · Cited by 7
Zhang, X., Yang, K., Wang, S., Tang, B., Yin, H., Lei, Q., Zhou, G., Gu, M., Shi, M., Zhao, C., et al. (2022) · Medicine · doi:10.1097/md.0000000000031533 · Cited by 6
The use of nonsteroidal anti - inflammatory drugs in polymorbid pathology
Asfandiyarova, N. S., & Филиппов, Е. В. (2020) · Terapevticheskii arkhiv · doi:10.26442/00403660.2020.01.000480 · Cited by 6
Tyler, S. E. B., & Tyler, L. D. K. (2023) · Brain Disorders · doi:10.1016/j.dscb.2023.100094 · Cited by 7
Kopec, J. A., Sayre, E. C., Okhmatovskaia, A., Cibere, J., LI, L. C., Bansback, N. J., Wong, H., Ghanbarian, S., & Esdaile, J. M. (2021) · PLoS ONE · doi:10.1371/journal.pone.0261017 · Cited by 5
Inflammatory Diseases and Risk of Atherosclerotic Cardiovascular Disease: A New Focus on Prevention
Quispe, R., Varghese, B. T., & Michos, E. D. (2022) · Contemporary cardiology · doi:10.1007/978-3-030-98824-1_13 · Cited by 6
Nascimento, G. C., Vivanco-Estela, A. N., Ferrié, L., Figadère, B., Raisman‐Vozari, R., Michel, P. P., & Bel, E. A. D. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.177054 · Cited by 4
Investigating the potency of bioactive compounds from ficus religiosa as anti-inflammatory agent
Utami, W., Aziz, H. A., Nasrudin, D., Kusmawan, A., Anwar, Z., Maulana, M., & Daryanto, M. (2021) · Journal of Physics Conference Series · doi:10.1088/1742-6596/1869/1/012022 · Cited by 4
Cardiovascular Risks of Nonsteroidal Anti-Inflammatory Drugs
Elliott, A., Juresic, S., Siegel, L. R., & Smith, N. T. (2025) · Clinical Journal of Pain · doi:10.1097/ajp.0000000000001341 · Cited by 3
Morozova, O. Y. (2022) · Integrative Physiology · doi:10.33910/2687-1270-2021-2-4-390-398 · Cited by 3
Choo, B.-K., Li, N., Nam, H., & Park, J.-C. (2020) · Pharmacognosy Magazine · doi:10.4103/pm.pm_57_19 · Cited by 3
Expert consensus on glucocorticoids injection for knee osteoarthritis
Huang, Y., & Liu, P. (2026) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-025-06363-1 · Cited by 2
Acute issues in the pharmacotherapy of hand osteoarthritis
Громова, О. А., Torshin, I. Y., Naumov, A. V., Vasilyeva, L. V., Evstratova, E. F., & Gromov, A. N. (2021) · FARMAKOEKONOMIKA Modern Pharmacoeconomics and Pharmacoepidemiology · doi:10.17749/2070-4909/farmakoekonomika.2020.067 · Cited by 2
Effects of Celecoxib on the QTc Interval: A Thorough QT/QTc Study
Kim, S., Lee, H., Ko, J., & Kim, J. (2019) · Clinical Therapeutics · doi:10.1016/j.clinthera.2019.09.004 · Cited by 2
Anti-inflammatory and antipyretic analgesics and drugs used in gout
Long, B., & Olah, M. E. (2020) · Side effects of drugs annual · doi:10.1016/bs.seda.2020.09.011 · Cited by 2
Atkinson, T. J., Petway, J., Forbes, W., Thorfinnson, H., Costantino, R. C., & Gressler, L. E. (2025) · Journal of Pain Research · doi:10.2147/jpr.s503743 · Cited by 1
Des recommandations sur la prise en charge de la coxarthrose : lecture critique
Choueiri, M., Eymard, F., & Chevalier, X. (2019) · Revue du Rhumatisme Monographies · doi:10.1016/j.monrhu.2019.07.001 · Cited by 1
Angeletti, F., Meier, F., Zöller, N. N., Meißner, M., Kaufmann, R., & Valesky, E. M. (2020) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.14292_g · Cited by 1
Initial drug prescription in outpatient department: principal approach
Karateev, A. E. (2021) · Modern Rheumatology Journal · doi:10.14412/1996-7012-2021-3-91-97
(2022) · Elsevier eBooks · doi:10.1016/b978-3-437-23673-0.00006-9
Regional Anesthesia and Pain Management for Total Hip Arthroplasty
Lee, B. H., Mamic, M., & Liu, J. (2023) · Oxford University Press eBooks · doi:10.1093/med/9780197518519.003.0027
Ivashchenko, T. V., Vartanyan, V. A., Sevriugina, E. A., Chkareuli, D. N., & Kazakova, M. S. (2024) · BIO Web of Conferences · doi:10.1051/bioconf/20248403027
RetractedMahmood, A., Chaudhry, R., Moazam, M., Zahee, M. T., & Ullah, I. (2024) · Journal of Advances in Medicine and Medical Research · doi:10.9734/jammr/2024/v36i55427 · Cited by 1
Ordyakova, A. A., Tyapkina, M. A., & Rebrov, A. P. (2024) · Russian Journal of Preventive Medicine · doi:10.17116/profmed20242706168
Nurmesa, A., Zakiyah, N., & Insani, W. N. (2025) · International Medical Case Reports Journal · doi:10.2147/imcrj.s488796
Nonsurgical treatment for young patients with glenohumeral osteoarthritis: a review
Fleshman, B., Marx, A., Sanders, A., & Jaeger, E. (2025) · Current Orthopaedic Practice · doi:10.1097/bco.0000000000001314
Komatsu, R., Singleton, M. D., Dinges, E. M., Wu, J., & Bollag, L. A. (2024) · Figshare · doi:10.6084/m9.figshare.25727870
The impact of anti-gout medications on eight cardiovascular diseases: a Mendelian randomized study
Peng, P., Wang, J., Huang, M., Hu, C., Liu, S., Liu, J., Cai, J., Wei, X., & Sun, H. (2026) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-025-03984-7
Choosing NSAID treatment in axial spondyloarthritis: factors guiding clinical decision-making
Gensler, L. S., McKay, C. E., & Mayer, A. S. (2026) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000001164
Repurposing anti-inflammatory therapeutics for disorders of the microbiome-gut-brain axis
Habib, Y. H., Gwaily, N. A., Ali, M. Y., Fawzy, M. A., Zakaria, M. A., & Ali, M. A. (2026) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2026.579000
Peripheral targets for neuropathic pain
Afsharipour, A., Ciotu, C. I., Resch, F. J., & Fischer, M. J. M. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70553
Chenxi, D., Miaomiao, W., Fan, J., Hongming, Z., Lu, G., Wang, L., Ying, Z., Xiaoqing, C., Zhang, J., & Sun, Y. (2026) · Journal of Thermal Biology · doi:10.1016/j.jtherbio.2026.104557 · Cited by 1
Metadata
- Authors
- Martín Arias, L. H., Martín González, A., Sanz Fadrique, R., & Vazquez, E. S.
- Affiliations
- Centre for Drug Surveillance (CESME) School of Medicine, Valladolid University Valladolid Spain
- Department of Pharmacy Sagrado Corazón Hospital Valladolid Spain
- Centre for Drug Surveillance (CESME) School of Medicine, Valladolid University Valladolid Spain
- Pharmacology, School of Medicine, Oviedo University Oviedo Spain
- Venue
- The Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2018-09-11
- Volume
- 59
- Issue
- 1
- Pages
- 55-73
- ISSN
- 0021-9754 (ISSN-L)
- 0091-2700
- 1552-4604
- OpenAlex
- W2891937954
- Cited by
- 68
- References
- 107
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 10 · 2023: 7 · 2022: 12 · 2021: 9 · 2020: 10 · 2019: 6 · 2018: 1
- FWCI
- 0.76
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- Locations
- The Journal of Clinical Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Consultation of the Doctoral Thesis Database (TESEO) (Ministerio de Educación, Cultura y Deporte) (submittedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Eicosanoids and Hypertension Pharmacology
- Keywords
- cardiovascular risk, nonsteroidal anti-inflammatory drugs, COX-2 inhibitors, rofecoxib, diclofenac, etoricoxib, celecoxib, cardiovascular adverse events, vascular events, drug safety, relative risk, observational studies, non-selective NSAIDs
- MeSH terms
- Celecoxib, Etoricoxib, Anti-Inflammatory Agents, Non-Steroidal, Cardiovascular Diseases, Humans, Risk Factors, Cohort Studies, Case-Control Studies, Observational Studies as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.